Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Jun-29-13 | Jun-30-12 | Jun-25-11 | Jun-26-10 | Jun-27-09 | Jun-26-08 | Jun-27-07 | Jun-28-06 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Consumer Healthcare | 2,089.0 | 1,815.8 | 1,684.9 | 1,573.7 | 1,412.6 | 1,336.1 | 1,037.3 | 994.2 |
| ConsumerHealthcare | 2,089.0 | 1,815.8 | 1,684.9 | 1,573.7 | 1,412.6 | | | |
| Rx Pharmaceuticals | 709.5 | 617.4 | 343.7 | 237.6 | 163.9 | 161.3 | 137.8 | 120.9 |
| Rx Pharma-ceuticals | 709.5 | 617.4 | 343.7 | 237.6 | 163.9 | | | |
| Other | | | | | | 232.5 | 193.2 | 251.6 |
| Total revenues | 3,539.8 | 3,173.2 | 2,755.0 | 2,268.2 | 2,005.6 | 1,729.9 | 1,368.4 | 1,366.8 |
| Revenue growth [+] | 11.6% | 15.2% | 21.5% | 13.1% | 15.9% | 26.4% | 0.1% | |
| Consumer Healthcare | 15.0% | 7.8% | 7.1% | 11.4% | 5.7% | 28.8% | 4.3% | |
| ConsumerHealthcare | 15.0% | 7.8% | 7.1% | 11.4% | | | | |
| Rx Pharmaceuticals | 14.9% | 79.6% | 44.7% | 44.9% | 1.7% | 17.0% | 13.9% | |
| Rx Pharma-ceuticals | 14.9% | 79.6% | 44.7% | 44.9% | | | | |
| Nutritionals | 1.5% | -0.5% | 94.1% | 14.5% | | | | |
| Cost of goods sold | 2,259.8 | 2,077.7 | 1,810.2 | 1,521.9 | 1,408.5 | 1,212.2 | 1,001.2 | 972.4 |
| Gross profit | 1,280.0 | 1,095.5 | 944.8 | 746.2 | 597.1 | 517.7 | 367.2 | 394.4 |
| Gross margin | 36.2% | 34.5% | 34.3% | 32.9% | 29.8% | 29.9% | 26.8% | 28.9% |
| Selling, general and administrative [+] | 473.8 | 411.8 | 364.4 | 298.3 | 255.9 | 245.6 | 193.6 | 219.2 |
| Sales and marketing | | | | | | 25.2 | 23.5 | 27.3 |
| General and administrative | | | | | | 220.4 | 170.1 | 191.9 |
| Research and development | 115.2 | 105.8 | 89.3 | 83.5 | 76.8 | 72.2 | 66.5 | 52.3 |
| Other operating expenses | 9.0 | -0.1 | -0.1 | | 0.3 | | | |
| EBITDA [+] | 842.2 | 713.3 | 594.1 | 438.5 | 335.4 | 269.2 | 165.1 | 179.5 |
| EBITDA growth | 18.1% | 20.1% | 35.5% | 30.7% | 24.6% | 63.0% | -8.0% | |
| EBITDA margin | 23.8% | 22.5% | 21.6% | 19.3% | 16.7% | 15.6% | 12.1% | 13.1% |
| Depreciation | 66.2 | 60.5 | 56.1 | 49.0 | 47.7 | 69.2 | 58.0 | 56.6 |
| EBITA | 776.0 | 652.8 | 538.0 | 389.5 | 287.7 | 200.0 | 107.1 | 122.9 |
| EBITA margin | 21.9% | 20.6% | 19.5% | 17.2% | 14.3% | 11.6% | 7.8% | 9.0% |
| Amortization of intangibles | 94.0 | 74.8 | 46.8 | 25.1 | 23.6 | | | |
| EBIT [+] | 682.0 | 578.0 | 491.2 | 364.4 | 264.1 | 200.0 | 107.1 | 122.9 |
| EBIT growth | 18.0% | 17.7% | 34.8% | 38.0% | 32.1% | 86.7% | -12.9% | |
| EBIT margin | 19.3% | 18.2% | 17.8% | 16.1% | 13.2% | 11.6% | 7.8% | 9.0% |
| Non-recurring items [+] | 2.9 | 8.8 | 1.0 | 28.5 | 14.6 | 5.1 | 9.1 | 8.8 |
| In-process research & development | | | | 19.0 | | 2.8 | 8.3 | |
| Interest expense, net [+] | 65.8 | 60.7 | 42.3 | 28.4 | 27.0 | -17.4 | -16.1 | -15.2 |
| Interest expense | 65.8 | 60.7 | 42.3 | 28.4 | 27.0 | | | |
| Interest income | | | | | | 17.4 | 16.1 | 15.2 |
| Other income (expense), net [+] | -5.6 | 3.5 | 2.7 | 1.2 | -16.2 | -34.3 | -26.9 | -23.4 |
| Other | -0.9 | 3.5 | 2.7 | 1.2 | -1.1 | 0.5 | 5.3 | -7.0 |
| Pre-tax income | 607.7 | 512.0 | 450.6 | 308.6 | 206.3 | 177.9 | 87.1 | 105.9 |
| Income taxes | 165.8 | 119.0 | 110.0 | 84.2 | 63.5 | 37.7 | 14.3 | 34.5 |
| Tax rate | 27.3% | 23.2% | 24.4% | 27.3% | 30.8% | 21.2% | 16.4% | 32.6% |
| Earnings from continuing ops | 441.9 | 384.4 | 342.0 | 225.1 | 140.1 | 140.2 | 72.8 | 71.4 |
| Earnings from discontinued ops | | 8.6 | -1.4 | -0.6 | 2.7 | -4.4 | 1.0 | |
| Net income | 441.9 | 393.0 | 340.6 | 224.4 | 142.8 | 135.8 | 73.8 | 71.4 |
| Net margin | 12.5% | 12.4% | 12.4% | 9.9% | 7.1% | 7.8% | 5.4% | 5.2% |
| |
| Basic EPS [+] | $4.71 | $4.12 | $3.71 | $2.46 | $1.52 | $1.51 | $0.79 | $0.77 |
| Growth | 14.1% | 11.3% | 50.5% | 62.0% | 1.0% | 90.6% | 2.7% | |
| Diluted EPS [+] | $4.68 | $4.09 | $3.66 | $2.42 | $1.50 | $1.47 | $0.78 | $0.76 |
| Growth | 14.5% | 11.7% | 50.9% | 62.0% | 1.6% | 89.7% | 2.3% | |
| |
| Dividends per share [+] | $0.35 | $0.31 | $0.27 | $0.24 | $0.22 | $195.00 | $178.00 | $168.00 |
| Growth | 12.9% | 13.8% | 12.4% | 12.8% | -99.9% | 9.6% | 6.0% | |
| |
| Shares outstanding (basic) [+] | 93.9 | 93.2 | 92.3 | 91.4 | 92.2 | 93.1 | 92.2 | 92.9 |
| Growth | 0.8% | 1.0% | 1.0% | -0.9% | -1.0% | 1.0% | -0.7% | |
| Shares outstanding (diluted) [+] | 94.5 | 94.1 | 93.5 | 92.8 | 93.6 | 95.2 | 93.8 | 94.1 |
| Growth | 0.4% | 0.6% | 0.7% | -0.8% | -1.7% | 1.5% | -0.3% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|